In the diabetic nephropathy mice experiment model, troglitazone a peroxisome proliferator -activated receptor gamma (PPAR gamma) agonists, ameliorate renal fibrotic lesions through reverse high glucose induced expressions of GSK-3β and inhibition epithelial-mesenchymal transition [5]. This evidence concerns the gene GSK3B and diabetic kidney disease.